Table 2.
OGD and biopsy findings from studies investigating EoE in adult patients presenting with FBO
| Study | Diagnosed with EoE (% cohort biopsied) | Number biopsied (% of OGD cohort) | OGD cohort | Diagnostic criteria |
| Desai et al 3 | 17 (54.8%) | 31 (100%) | 31 | Biopsies from upper and lower oesophagus, stomach and duodenum. ≥20 eos/hpf 13/17 pre-treated with PPI for 4–8 |
| Kerlin et al 14 | 14 (48.3%) | 29 (67.4%) | 43 | Biopsies from proximal and distal oesophagus, ≥15 eos/hpf |
| Sperry et al 15 | 45 (46%) | 98 (27%) | 363 | ≥15 eos/hpf, lack of response to PPI or normal pH monitoring. |
| Mahesh et al 2 | 73 (52%) | 141 (45%) | 315 | >15/eos/hpf+other descriptive histological findings, no specified oesophageal biopsy location |
| Heerasing et al 16 | 17 (33%) | 51 (60%) | 85 | Biopsies from proximal and distal oesophagus, ≥20 eos/hpf |
| Philpott et al 17 | 85 (30.6%) | 278 (24.6%) | 1132 | ≥15 eos/hpf, no specified oesophageal biopsy location |
| Truskaite and Dlugosz18 | 34 (18%) | 185 (77.7%) | 238 | Biopsies from proximal, mid, distal oesophagus, antrum and duodenum. ≥15 eos/hpf after PPI treatment |
| Our study | 21 (26.3%) | 80 (39.6%) | 202 | ≥15 eos/hpf, or diagnosis of EoE suggested on histopathology report |
EoE, eosinophilic oesophagitis; FBO, food bolus obstruction; OGD, oesophagogastroduodenoscopy; PPI, proton pump inhibitor; eos/hpf, eosinophils per high-power field.